Tumor-Targeted Interleukin 2 Boosts the Anticancer Activity of FAP-Directed Radioligand Therapeutics

Conclusion: The combination of OncoFAP-based radioligand therapeutics with concurrent targeting of interleukin 2 shows synergistic anticancer effects in the treatment of FAP-positive tumors. This experimental finding should be corroborated by future clinical studies.

Source: Journal of Nuclear Medicine - December 1, 2023 Category: Nuclear Medicine Authors: Galbiati, A., Dorten, P., Gilardoni, E., Gierse, F., Bocci, M., Zana, A., Mock, J., Claesener, M., Cufe, J., Buther, F., Schafers, K., Hermann, S., Schafers, M., Neri, D., Cazzamalli, S., Backhaus, P. Tags: Basic Science Investigations Source Type: research